Advertisement

Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones

Published:March 05, 2020DOI:https://doi.org/10.1016/j.cgh.2020.02.053

      Background and Aims

      Proton pump inhibitors (PPIs) are widely prescribed and have effects on gut ion absorption and urinary ion concentrations. PPIs might therefore protect against or contribute to development of kidney stones. We investigated the association between PPI use and kidney stones.

      Methods

      We performed a retrospective study using data from the Women’s Veteran’s Cohort Study, which comprised men and women, from October 1, 1999 through September 30, 2017. We collected data from 465,891 patients on PPI usage over time, demographics, laboratory results, comorbidities, and medication usage. Time-varying Cox proportional hazards and propensity matching analyses determined risk of PPI use and incident development of kidney stones. Use of histamine-2 receptor antagonists (H2RAs) was measured and levothyroxine use was a negative control exposure.

      Results

      PPI use was associated with kidney stones in the unadjusted analysis, with PPI use as a time-varying variable (hazard ratio [HR], 1.74; 95% CI, 1.67–1.82), and persisted in the adjusted analysis (HR, 1.46; CI, 1.38–1.55). The association was maintained in a propensity score-matched subset of PPI users and nonusers (adjusted HR, 1.25; CI 1.19–1.33). Increased dosage of PPI was associated with increased risk of kidney stones (HR, 1.11; CI, 1.09–1.14 for each increase in 30 defined daily doses over a 3-month period). H2RAs were also associated with increased risk (adjusted HR, 1.47; CI 1.31–1.64). We found no association, in adjusted analysis, of levothyroxine use with kidney stones (adjusted HR, 1.06; CI 0.94–1.21).

      Conclusions

      In a large cohort study of veterans, we found PPI use to be associated with a dose-dependent increase in risk of kidney stones. H2RA use also has an association with risk of kidney stones, so acid suppression might be an involved mechanism. The effect is small and should not change prescribing for most patients.

      Keywords

      Abbreviations used in this paper:

      CI (confidence interval), DDD (defined daily dose), GERD (gastroesophageal reflux disease), GI (gastrointestinal), H2RA (histamine-2 receptor antagonist), HR (hazard ratio), PPI (proton pump inhibitor), VHA (Veterans Health Administration), eGFR (estimated glomerular filtration rate)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Katz P.O.
        • Gerson L.B.
        • Vela M.F.
        Guidelines for the diagnosis and management of gastroesophageal reflux disease.
        Am J Gastroenterol. 2013; 108 (quiz 329): 308-328
        • Leontiadis G.I.
        • McIntyre L.
        • Sharma V.K.
        • et al.
        Proton pump inhibitor treatment for acute peptic ulcer bleeding.
        Cochrane Database Syst Rev. 2004; 3: CD002094
        • Forgacs I.
        • Loganayagam A.
        Overprescribing proton pump inhibitors.
        BMJ. 2008; 336: 2
        • Heidelbaugh J.J.
        • Kim A.H.
        • Chang R.
        • et al.
        Overutilization of proton-pump inhibitors: what the clinician needs to know.
        Therap Adv Gastroenterol. 2012; 5: 219-232
        • Luo H.
        • Fan Q.
        • Xiao S.
        • et al.
        Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
        BMC Health Serv Res. 2018; 18: 537
        • Yang Y.X.
        • Lewis J.D.
        • Epstein S.
        • et al.
        Long-term proton pump inhibitor therapy and risk of hip fracture.
        JAMA. 2006; 296: 2947-2953
        • Trifan A.
        • Stanciu C.
        • Girleanu I.
        • et al.
        Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis.
        World J Gastroenterol. 2017; 23: 6500-6515
        • Ito T.
        • Jensen R.T.
        Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.
        Curr Gastroenterol Rep. 2010; 12: 448-457
        • Mizunashi K.
        • Furukawa Y.
        • Katano K.
        • et al.
        Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.
        Calcif Tissue Int. 1993; 53: 21-25
        • William J.H.
        • Nelson R.
        • Hayman N.
        • et al.
        Proton-pump inhibitor use is associated with lower urinary magnesium excretion.
        Nephrology (Carlton). 2014; 19: 798-801
        • Yang Y.-X.
        Chronic proton pump inihibitor therapy and calcium metabolism.
        Curr Gastroenterol Rep. 2012; 14: 473-479
        • Curhan G.C.
        • Willett W.C.
        • Rimm E.B.
        • et al.
        A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones.
        N Engl J Med. 1993; 328: 833-838
        • Sorensen M.D.
        Calcium intake and urinary stone disease.
        Transl Androl Urol. 2014; 3: 235-240
        • Su C.J.
        • Shevock P.N.
        • Khan S.R.
        • et al.
        Effect of magnesium on calcium oxalate urolithiasis.
        J Urol. 1991; 145: 1092-1095
        • Fetner C.D.
        • Barilla D.E.
        • Townsend J.
        • et al.
        Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis.
        J Urol. 1978; 120: 399-401
        • Haskell S.G.
        • Mattocks K.
        • Goulet J.L.
        • et al.
        The burden of illness in the first year home: do male and female VA users differ in health conditions and healthcare utilization.
        Womens Health Issues. 2011; 21: 92-97
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Harrold L.R.
        • Saag K.G.
        • Yood R.A.
        • et al.
        Validity of gout diagnoses in administrative data.
        Arthritis Rheum. 2007; 57: 103-108
        • Laine L.
        • Yang H.
        • Chang S.C.
        • et al.
        Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009.
        Am J Gastroenterol. 2012; 107 (quiz 1196): 1190-1195
        • Miller D.R.
        • Safford M.M.
        • Pogach L.M.
        Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data.
        Diabetes Care. 2004; 27: B10-B21
        • Tasian G.E.
        • Ross M.E.
        • Song L.
        • et al.
        Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012.
        Clin J Am Soc Nephrol. 2016; 11: 488-496
        • World Health Organization Collaborating Centre for Drug Statistics Methodology
        Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD).
        (Available at:)
        • Zhang Z.
        • Reinikainen J.
        • Adeleke K.A.
        • et al.
        Time-varying covariates and coefficients in Cox regression models.
        Ann Transl Med. 2018; 6: 121
        • Austin P.C.
        Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.
        Stat Med. 2009; 28: 3083-3107
        • Dusetzina S.B.
        • Brookhart M.A.
        • Maciejewski M.L.
        Control outcomes and exposures for improving internal validity of nonrandomized studies.
        Health Serv Res. 2015; 50: 1432-1451
        • Massey L.
        Magnesium therapy for nephrolithiasis.
        Magnes Res. 2005; 18: 123-126
      1. Ferraro P CG, Gambaro G, Taylor E. Proton pump inhibitors, histamine receptor–2 blockers and the risk of incident kidney stones. Presented at: American Society of Nephrology Kidney Week; November 17–20, 2016; Chicago, Illinois.

        • Ettinger B.
        • Pak C.Y.
        • Citron J.T.
        • et al.
        Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis.
        J Urol. 1997; 158: 2069-2073
        • Han H.
        • Segal A.M.
        • Seifter J.L.
        • et al.
        Nutritional management of kidney stones (nephrolithiasis).
        Clin Nutr Res. 2015; 4: 137-152
        • Moayyedi P.
        Making sense of the adverse effects of PPIs. AGA Perspectives. 2016.
        (Available at:)
        • Targownik L.E.
        • Metge C.
        • Roos L.
        • et al.
        The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.
        Am J Gastroenterol. 2007; 102: 942-950
        • Dublin S.
        • Walker R.L.
        • Jackson M.L.
        • et al.
        Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
        Pharmacoepidemiol Drug Saf. 2010; 19: 792-802
        • Moayyedi P.
        • Eikelboom J.W.
        • Bosch J.
        • et al.
        Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.
        Gastroenterology. 2019; 157: 682-691.e2

      Linked Article

      • Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and the Risk of Kidney Stones: Negligible or Not?
        Clinical Gastroenterology and HepatologyVol. 19Issue 3
        • Preview
          We read with great interest the study from Simonov et al,1 the first study examining the association of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) with the risk of kidney and ureteral stone development. PPIs are the mainstay of acute and long-term management of acid-related disease, especially gastroesophageal reflux disease; delay progression of Barrett’s esophagus to dysplasia; and can prevent gastrointestinal bleeding in patients on antiplatelet or anticoagulant therapy.
        • Full-Text
        • PDF